Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KX-826 (Pyrilutamide) Phase II in Male Androgenetic Alopecia
NCT05940506Phase 2Completed
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- Sep 2020
- Primary completion
- Jul 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of pyrilutamide in androgenetic alopecia (AGA), sponsored by Kintor Pharmaceutical Limited. Started Sep 2020; status: completed.
02
Drugs
pyrilutamide
03
Conditions
androgenetic alopecia (AGA)
Beyond the preview
Go deeper on NCT05940506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940506.